The major focus of Dr. Manji’s research is the investigation of disease and treatment-induced changes in synaptic and neural plasticity in neuropsychiatric disorders. Dr. Manji has helped to discover, develop, and launch several new medications for serious neuropsychiatric and neurodegenerative disorders. These include the first novel antidepressant mechanism in over 30 years, the first medication in Neuroscience granted FDA “Breakthrough designation”, a once every 6-month treatment for schizophrenia, novel mechanism(s) for Alzheimer’s Disease, multiple sclerosis among others. Dr. Manji also has been actively involved in developing biomarkers to help refine these multifactorial diseases, and to develop a holistic approach towards neuropsychiatric and neurodegenerative disorders.
Dr. Manji has received a number of prestigious awards, including the NIMH Director’s Career Award for Significant Scientific Achievement, PhRMA Research & Hope Award for Excellence in Biopharmaceutical Research, the American Federation for Aging Research Award of Distinction, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the ACNP’s Joel Elkes Award for Distinguished Research, the DBSA Klerman Senior Distinguished Researcher Award, the Briggs Pharmacology Lectureship Award, the Caring Kind Alzheimer’s Disease Leadership Award, and the Global Health & the Arts Award of Recognition, and has also been recognized as one of 14 inaugural “Health Heroes” by Oprah magazine.
link
